CFH and LOC387715/ARMS2 Genotypes and Treatment with Antioxidants and Zinc for Age-Related Macular Degeneration
- 17 April 2008
- journal article
- research article
- Published by Elsevier in Ophthalmology
- Vol. 115 (6) , 1019-1025
- https://doi.org/10.1016/j.ophtha.2008.01.036
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degenerationProceedings of the National Academy of Sciences, 2007
- Structural basis for complement factor H–linked age-related macular degenerationThe Journal of Experimental Medicine, 2007
- Variation in complement factor 3 is associated with risk of age-related macular degenerationNature Genetics, 2007
- Biochemical Analysis of a Common Human Polymorphism Associated with Age-Related Macular DegenerationBiochemistry, 2007
- Ornithine Decarboxylase Polymorphism Modification of Response to Aspirin Treatment for Colorectal Adenoma PreventionJNCI Journal of the National Cancer Institute, 2006
- Mechanisms of Disease: oxidative stress and inflammation in the pathogenesis of hypertensionNature Clinical Practice Nephrology, 2006
- Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degenerationNature Genetics, 2006
- Overview of the pharmacogenetics of asthma treatmentThe Pharmacogenomics Journal, 2006
- Complement Factor H Polymorphism in Age-Related Macular DegenerationScience, 2005
- Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degenerationOphthalmology, 1999